Search

everythinglearnresearchcommunity

for

Search:↓

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

Significant hair regrowth was achieved over six months using minoxidil, finasteride, microneedling, biotin and collagen shampoo, and MSM powder. The user feels more confident and may consider a hair transplant if necessary.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.

The user shared progress on hair regrowth using a topical minoxidil/finasteride spray, dermarolling weekly, and a product similar to pp405. They reported some regrowth with no side effects from the new product.

PP-405, a potential hair loss treatment, shows promise in stimulating dormant hair follicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The user shared progress after six months using a topical mix of 0.3% finasteride and 6% minoxidil, reporting significant hair regrowth with minimal side effects. The product used is a spray from Hims, applied to the crown before bed.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.

A 46-year-old shared 1.6 years of hair regrowth progress using a regimen that includes Minoxidil, Finasteride, and possibly other treatments. Suggestions included considering a hair transplant, using dutasteride, and adding tretinoin for further improvement.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

A 30-year-old MTF individual shared a 6-month update on hair loss improvement using minoxidil, retinol, and microneedling, along with lowering testosterone to reduce DHT. They reported positive results, feeling happier and more confident.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

The post discusses the experiences of individuals with diffuse hair thinning using finasteride, with many reporting no improvement or worsening conditions after 6 months. Various suggestions include persisting with the treatment, checking for underlying conditions, adding minoxidil for volume, adjusting dosage, and considering other potential causes like autoimmune responses and inflammation.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

A man shared his 6.5-month progress using finasteride, a derma roller, and biotin supplements for hair loss, with no side effects and overcoming two shedding phases. Commenters are impressed, noting hairline improvement and discussing the potential of these treatments in regrowing hair, especially at the temples.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

People are discussing obtaining and testing PP405 for hair loss treatment, with concerns about its purity and effectiveness. Some are considering delaying hair transplants, while others suggest using existing treatments like finasteride and minoxidil.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

JeremySoCa's DHT level was 29 ng/dl, considered low, and Estradiol was 26.1 pg/dl within the normal range. They are using topical finasteride for hair loss and had a thyroidectomy due to Graves' disease.

A user shared their 6-month update on hair loss treatment, using daily Dutasteride, oral and topical Minoxidil, Ketoconazole shampoo, topical Finasteride, dermastamping, and PRP treatments. They reported improved hair quality but no significant regrowth or density increase, and plan to continue the regimen for another year before considering a hair transplant.

The user is using a treatment of topical minoxidil 7% and finasteride 0.1% twice daily, along with a low-level laser therapy cap, biotin, and collagen supplements, and is seeing good progress on the hairline and temples but not the midscalp. They experienced initial shedding, saw results by month three, and are happy with the progress, though some users express concern about using finasteride at a young age.

People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.

A 22-year-old is experiencing hair thinning and is using oral finasteride and minoxidil chewables, along with microneedling and anti-dandruff shampoo, to manage it. Despite experiencing significant shedding, they remain hopeful for regrowth in the coming months.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

A 21-year-old is using finasteride and previously used minoxidil for hairline concerns, considering a hair transplant despite no visible balding. They are advised to continue finasteride as a preventive measure.